BRIEF-Beam Therapeutics Says It Sets Strategic Priorities For Its Genetic Disease & Hematology Franchises

Beam Therapeutics +1.82%

Beam Therapeutics

BEAM

24.66

+1.82%

Jan 11 (Reuters) - Beam Therapeutics Inc BEAM.O:

  • BEAM THERAPEUTICS SETS STRATEGIC PRIORITIES FOR ITS GENETIC DISEASE AND HEMATOLOGY FRANCHISES TO DRIVE EXECUTION OF LATE-STAGE CLINICAL PROGRAMS AND EXTENDS ITS OPERATING RUNWAY THROUGH COMMERCIAL TRANSITION

  • BEAM THERAPEUTICS INC - FDA ALIGNMENT ON ACCELERATED APPROVAL PATHWAY FOR BEAM-302

  • BEAM THERAPEUTICS INC - RISTO-CEL BLA SUBMISSION EXPECTED BY YEAR-END 2026

  • BEAM THERAPEUTICS INC - TO ANNOUNCE NEW LIVER-TARGETED PROGRAM IN H1 2026

Source text: ID:nGNX4ct14z

Further company coverage: BEAM.O


((Reuters.Briefs@thomsonreuters.com;))

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.